Future Directions in Cancer Immunotherapy with Monoclonal Antibodies

Abstract

Cancer immunotherapy, particularly with monoclonal antibodies (mAbs), has revolutionized oncology. This article explores the current landscape and future prospects of mAb-based immunotherapies. We discuss novel targets, combination strategies, and emerging technologies like bispecific antibodies and antibody-drug conjugates. Key challenges, such as resistance mechanisms and toxicity, are addressed, alongside potential solutions. The role of artificial intelligence in accelerating mAb discovery and optimizing treatment regimens is also examined. Ultimately, this review aims to provide a roadmap for advancing cancer immunotherapy and improving patient outcomes.